Top Stories

As Psychedelics Enter the Mainstream, Mining Companies Look to Dig Up Profits

Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.

An Open Letter and Call to Action for MAPS Canada

The following is an open letter by two former co-leads of the MAPS Canada Diversity Committee. It was written in response to a variety of racist and prejudicial behaviours they experienced from MAPS Canada leadership and the organization at large during their eight-month tenure as unpaid volunteers, including obstruction—by leadership—of their efforts to address long-entrenched discriminatory practices in the psychedelic research domain and to implement initiatives to combat race-based health disparities.

Become a member

and support our work.

Press Release: Plus Three found to have neuroprotective effects against corporadelic BS

In this episode we explore the myriad of problems that result from media outlets treating corporate press releases as though they're legitimate news sources, rather than advertisements. We examine "science by press release" cases ranging from psychedelic pharmaceutical firms who claim their barely-studied compounds are superior to (and safer than) psilocybin (one of the safest psychoactive compounds in the human pharmacopoeia), to students who claimed Oreos were as addictive as cocaine, to pineal DMT, cold fusion, and more.

Join Our Newsletter

Independent drug journalism. In your inbox.

Popular Reads

Join Our

Independent drug journalism. In your inbox.

From Mining to Mushrooms

A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.


A series on the intersection of psychedelics and capitalism, and the early investors making it happen.